Five-month-old Jack Palmer is home with his family in Kansas City after undergoing an extremely rare heart-lung transplant at St. Louis Children’s and Washington University Heart Center in May. At five months of age, Jack was the youngest patient to undergo this surgery successfully in more than a decade.

New data announced at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, reinforce the safety, durability and consistency of the In.Pact Admiral drug-coated balloon (DCB) in real-world patients with peripheral arterial disease (PAD). Three-year real-world results from the full clinical cohort of the IN.PACT Global Study and one-year data from the Total IN.PACT pooled imaging and propensity analyses were presented at the TCT conference and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) annual meeting, Sept. 22-26 in Lisbon, Portugal, respectively.

September 24, 2018 — Getinge is voluntarily initiating a worldwide recall involving a field correction of approximately ...

At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, Siemens Healthineers will showcase new products that span the continuum of care in cardiology. Introducing solutions in both the laboratory and imaging spaces, Siemens Healthineers will debut a new ultrasound real-time intra-cardiac echo (ICE) catheter and High-Sensitivity Troponin I assays. The company is also a sponsor of the Interventional Imaging and Endovascular Pavilions at TCT, supplying hands-on workshops and simulations for continuing education.

At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing its latest solutions in interventional cardiology. These solutions combine imaging systems, planning and navigation software, and specialized diagnostic and therapeutic devices, helping clinicians conduct procedures that are fast, efficient and personalized.

September 19, 2018 — Abiomed Inc. announces its initiatives at the 30th Transcatheter Cardiovascular Therapeutics (TCT) ...

The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to initiate a new single-arm study of Medtronic’s CoreValve Evolut transcatheter aortic valve replacement (TAVR) system in patients with bicuspid aortic valves. All patients in the study will be at low risk of surgical mortality. Medtronic separately received FDA approval for revised commercial labeling for the CoreValve Evolut TAVR system that removed a precaution for the treatment of bicuspid severe aortic stenosis patients deemed at intermediate or greater risk for surgical aortic valve replacement.